Literature DB >> 9406883

Characterization of ligand binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors.

J F Pregenzer1, G L Alberts, J H Bock, J L Slightom, W B Im.   

Abstract

The 5-HT1D receptor is a potential target of anti-migraine drugs, and here its genes were cloned from chimpanzee, gorilla and rhesus monkey, via polymerase chain reactions with their genomic DNAs and the primers designed from the 5' and 3' untranslated regions of the human receptor. Direct sequencing of the polymerase chain reaction (PCR) products revealed high degrees of identity between their deduced amino acid sequences (the chimpanzee, gorilla and rhesus monkey) and that of human, differing by two, four and 11 residues, respectively. The binding properties of the receptors, as expressed in human embryonic kidney 293 cells, were compared to those obtained with the human and guinea pig receptors, the latter differing by 33 residues from the human receptor. Standard serotonergic ligands including several indoles, ergots and methiothepin bound all the cloned primate and guinea pig receptors with comparable, low nanomolar affinities, leading to high correlation coefficients among their Ki values. R(+)-8-Hydroxydipropylaminotetralin, on the other hand, bound the human receptor with the affinity higher than those for the primates and guinea pig receptors. This indicates that certain chemical templates may differentiate the molecular divergences among the 5-HT1D receptors of various animal species, and the use of the non-human primates will be beneficial for pharmacological characterizations, more relevant to the human receptor, of future novel ligands for the 5-HT1D receptor, which are potential anti-migraine drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406883     DOI: 10.1016/s0304-3940(97)00728-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Efficient functional coupling of the human D3 dopamine receptor to G(o) subtype of G proteins in SH-SY5Y cells.

Authors:  P G Zaworski; G L Alberts; J F Pregenzer; W B Im; J L Slightom; G S Gill
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands).

Authors:  J F Pregenzer; G L Alberts; W B Im; J L Slightom; M D Ennis; R L Hoffman; N B Ghazal; R E TenBrink
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Molecular cloning, sequence analysis and pharmacological properties of the porcine 5-HT(1D) receptor.

Authors:  P Bhalla; H S Sharma; T Wurch; P J Pauwels; P R Saxena
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

4.  Advantages of heterologous expression of human D2long dopamine receptors in human neuroblastoma SH-SY5Y over human embryonic kidney 293 cells.

Authors:  G L Alberts; J F Pregenzer; W B Im
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

5.  The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology.

Authors:  Michael J Winkelman
Journal:  Front Neurosci       Date:  2017-09-28       Impact factor: 4.677

6.  'I Get High With a Little Help From My Friends' - How Raves Can Invoke Identity Fusion and Lasting Co-operation via Transformative Experiences.

Authors:  Martha Newson; Ragini Khurana; Freya Cazorla; Valerie van Mulukom
Journal:  Front Psychol       Date:  2021-09-24

Review 7.  Post-triptan era for the treatment of acute migraine.

Authors:  Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2004-10

8.  Recognition properties and competitive assays of a dual dopamine/serotonin selective molecularly imprinted polymer.

Authors:  Roongnapa Suedee; Vatcharee Seechamnanturakit; Acharee Suksuwan; Bhutorn Canyuk
Journal:  Int J Mol Sci       Date:  2008-11-26       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.